Although high, the rate of grade 3–4 neutropenia we reported in the period between RT end and the three following cycles of CDK4/6 inhibitors (61.1%) is consistent with that described with palbociclib alone3. The gene discussed is CDK4; the disease is Decreased total neutrophil count.